Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study

Página do item simplificado
dc.contributor.authorForgerini, Marcela [UNESP]
dc.contributor.authorHerdeiro, Maria Teresa
dc.contributor.authorGalduróz, José Carlos Fernandes
dc.contributor.authorMastroianni, Patrícia de Carvalho [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionInstitute of Biomedicine (iBiMED)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2020-12-12T02:16:41Z
dc.date.available2020-12-12T02:16:41Z
dc.date.issued2020-05-01
dc.description.abstractBACKGROUND: Improving knowledge and establishing strategies and policies for better patient safety are worldwide priorities. OBJECTIVE: To evaluate drug safety among elderly people with Alzheimer’s disease (AD). DESIGN AND SETTING: Cross-sectional study among elderly people within the National AD Assistance Protocol (PCDTDA/MS) who were living in the municipality of Araraquara, Brazil, in 2017. METHODS: Through interviews conducted with relatives/caregivers of elderly people with diagnoses of AD, the following variables were evaluated: comorbidities, drug therapy used, use of potentially inappropriate medications for the elderly (PIMs), presence of potentially inappropriate interactions (PIIs) and medication regimen complexity index. Factors associated with AD severity were also evaluated. Multivariate and simple logistic regressions were applied. RESULTS: 143 elderly people enrolled in PCDTDA/MS were analyzed. The majority were women (67.1%); assisted only through the public healthcare system (75.5%); polymedicated (57.4%); using at least one PIM (63.6%); presenting at least one PII (63.6%); and under drug therapy of low to medium complexity (92.2%). No semi-annual monitoring of the effectiveness of PCDTDA/MS drugs was identified. The proportion using AD drug therapy at daily doses differing from those recommended by the World Health Organization was 75.6%. However, these doses were not associated with drug risk. CONCLUSION: The data from this study raise the hypothesis that use of polypharmacy might show a correlation with severity of AD. The drug safety risk may be associated with comorbidities of the metabolic syndrome, anxiety and off-label use of PIMs, such as risperidone and quetiapine, and benzodiazepines (i.e. clonazepam and flunitrazepam).en
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences Universidade Estadual Paulista (UNESP)
dc.description.affiliationDepartment of Medical Sciences Universidade de Aveiro Institute of Biomedicine (iBiMED)
dc.description.affiliationDepartment of Psychobiology Universidade Federal de São Paulo (UNIFESP)
dc.description.affiliationDepartment of Drugs and Medicines Universidade Estadual Paulista (UNESP)
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences Universidade Estadual Paulista (UNESP)
dc.description.affiliationUnespDepartment of Drugs and Medicines Universidade Estadual Paulista (UNESP)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdCAPES: 001
dc.description.sponsorshipIdCNPq: 131206/2017-6
dc.description.sponsorshipIdFAPESP: 2013/12681-2
dc.description.sponsorshipIdFAPESP: 2018/07501-9
dc.description.sponsorshipIdCNPq: 459461/2014-1
dc.format.extent216-228
dc.identifierhttp://dx.doi.org/10.1590/1516-3180.2019.0461.r2.19022020
dc.identifier.citationSao Paulo Medical Journal, v. 138, n. 3, p. 216-228, 2020.
dc.identifier.doi10.1590/1516-3180.2019.0461.r2.19022020
dc.identifier.fileS1516-31802020000300216.pdf
dc.identifier.issn1516-3180
dc.identifier.scieloS1516-31802020000300216
dc.identifier.scopus2-s2.0-85088490771
dc.identifier.urihttp://hdl.handle.net/11449/200810
dc.language.isoeng
dc.relation.ispartofSao Paulo Medical Journal
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectDementia
dc.subjectPatient safety
dc.subjectPolypharmacy
dc.titleRisk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional studyen
dc.typeArtigo
unesp.author.orcid0000-0002-2905-8519[1]
unesp.author.orcid0000-0002-0500-4049[2]
unesp.author.orcid0000-0002-2710-9693[3]
unesp.author.orcid0000-0001-8467-7278[4]

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S1516-31802020000300216.pdf
Tamanho:
294.72 KB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Artigos - Fármacos e Medicamentos - FCFAR